Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Non-Small-Cell Lung Cancer (NSCLC)

FDA Approves Tabrecta, First Targeted Therapy for NSCLC

Posted on May 11, 2020
Post Views: 504

Non-Small-Cell Lung Cancer (NSCLC)The FDA has approved Tabrecta, Novartis for the treatment of non-small cell lung cancer (NSCLC) that has spread to other parts of the body. NSCLC is the most common type of lung cancer with up to 90% of all lung cancer patients come under this category. It has a high risk of cancer cells spreading to other regions of the body.

Richard Pazdur, MD, director of FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research said, “Tabrecta is the first approval specifically for the treatment of patients with non-small cell lung cancer whose tumors have mutations that lead to MET exon 14 skipping. This patient population now has an option for a targeted therapy, which they didn’t have prior to today.”

Tabrecta has been approved for both untreated as well as previously treated patients, irrespective of their previous type of treatment. It is the first approved treatment for specifically target METex14 mutated metastatic NSCLC. With this approval, Novartis beats Pfizer Inc in the race to develop treatment for NSCLC. This approval has been based on the results of a clinical trial involving patients with NSCLC with mutations that led to MET exon 14 skipping, epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) and at least one measurable lesion.

The common side effects for patients taking Tabrecta include leg swelling, shortness of breath, fatigue, nausea, vomiting and decreased appetite. Drugmakers like Novartis are increasing using biomarker-driven drugs for treatment of patients with rare tumors; only 3 to 4% of lung cancer patients have MET exon14 skipping mutation. Only about 4000-5000 patients are diagnosed with METex14 metastatic NSCLC each year in the United States.

The information shared in this blog is for educational purposes only.

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,324)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d